Kronik myeloid lösemide imatinibe alınan hematolojik, sitogenetik ve moleküler yanıt oranları: Türkiye’den tek merkez deneyimi

Amaç: İmatinib mesilat kronik myeloid lösemi (KML)’de hematolojik ve sitogenetik remisyonu takiben hastalığınilerlemesinde düzelmeyi indüklemektedir. Biz bu çalışmada tedaviye cevabı değerlendirmek istedik.Yöntem ve gereç: Çalışmaya Ocak 2006 ve Haziran 2009 yılları arasında Atatürk Üniversitesi Tıp Fakültesi HastanesiHematoloji bölümünde KML tanısıyla takib edien ve imatinib ile tedavi edilen 31 hasta alındı. Hastalara birincil veyaikincil olarak standart 400 mg/gün imatinib başlandı.Bulgular: Çalışmada 2. ay sonunda tüm hastalarda hematolojik yanıt sağlandı. 12. ay sonunda tam sitogentik yanıtoranı % 71 ve 24. ay sonunda tam moleküler yanıt oranı % 85’idi. En sık karşılaşılan yan etki ödemdi (yüzde ve/veyaakral bölgelerde). Çalışma sürecinde hiçbir hastada 3. veya 4. derece hematolojik yan etki gözlenmedi.Sonuç: Bizim çalışma sonuçlarımıza göre hastalarımızda imatinib tedavisi ile diğer ülkelerdekine bezer oranlarda tedavibaşarısı sağlanırken daha düşük oranlarda yan etki ile karşılaşılmıştır.

Anahtar Kelimeler:

Kronik myeloid lösemi, imatinib, cevap, sağkalım

Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey

To validate patient responses to imatinib mesylate, which induces hematologic and cytogenetic remission and, consequently, modifies the progression of chronic myeloid leukemia (CML). Materials and methods: Between January 2006 and July 2009, 31 patients with chronic-phase CML were treated with imatinib therapy in the hematology unit of Atatürk University Medical Faculty Training Hospital. Imatinib treatment was begun at the standard dose of 400 mg/day, as either first-line or second-line therapy. Results: At the end of the second month of treatment, all of the patients had achieved complete hematologic response. After 12 months, the rate of complete cytogenetic response was 71%, and after 24 months, the rate of complete molecular response was 85%. The most commonly observed adverse event was edema (facial and/or peripheral). No grade 3 or 4 hematological adverse events were observed during the study period. Conclusion: Our CML patients' responses to imatinib therapy were similar to those seen in other countries, although our group had a lower rate of adverse events.

Keywords:

imatinib, response, survival, Chronic myeloid leukemia,

PDF

___

Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40. 2. Kuzrock R, Gutterman JU, Talpaz M. Th e molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990-8.
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-17.
Deninger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008; 419-26.
Kujawski LA, Talpaz M. Th e role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine & Growth Factor Reviews 2007; 18: 459-71.
Hochhaus A. Minimal residual disease in chronic myeloid leukemia patients. Best Pract Res Clin Haematol 2002; 15: 159- 78.
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-32.
Vardiman JW, Melo JV, Baccarini M, Th iele J. Chronic myelogenous leukemia BCR-ABL 1 positive. In: Steven HS, Elias C, Nancy LH, editors. WHO classifi cation of tumors of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. p.32-7.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology, v. 1. 2007; 1-48. Available from: URL: http://www.nccn.org.
Cancer Th erapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003; 1-34. Available from: URL: http://ctep. cancer.gov.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low- dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
O’Brien S, Guilhot F, Druker B, Goldman J, Hochhaus A, Hughes T et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). American Society of Hematology Annual Meeting 2008; 186.
Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W et al. Effi cacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 2009; 89: 445- 51.
Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M. Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase. Haematologica 2007; 92: 1579-80.
Nannya Y, Yokota H, Sato Y, Yamamoto G, Takashi A, Motoshi I et al. Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. Int J Hematol 2008; 88: 159- 64.
Sugita J, Tanaka J, Kurosawa M, Fukuhara T, Hashino S, Torimoto E et al. Eff ects of the mean daily doses of imatinib during the fi rst year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group. Eur J Haematol 2008; 80: 160-3.
Faber E, Nausová J, Jarosová M, Egorin MJ, Holzerová M, Rozmanová S et al. Intermittent dosage of imatinib mesylate in CML patients with a history of signifi cant hematologic toxicity aft er standard dosing. Leuk Lymphoma 2006; 47: 1082-90.
Mauro MJ, Druker BJ. STI571: Targeting BCR-ABL as therapy for CML. Oncologist 2001; 6: 233-8.
Cortes J, Giles F, O’Brien S, Th omas D, Garcia-Manero G, Rios MB et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome: positive chronic myeloid leukemia aft er failure of interferon-alpha. Blood 2003; 102: 83-6.
Th omas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-45.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Effi cacy and safety of a specifi c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
Kantarjian HM, Cortes J. New strategies in chronic
myelogenous leukemia (CML). Leukemia Insights 2006; 11: 1-7.
Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G,
Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome- positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-8.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-51.
Huntly BJP, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732-8.
Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738-43.
Huntly BJP, Bench AJ, Delabesse E, Reid AG., Li J, Scott MA et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL- BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002; 99: 4547-53.